Topic: Nih

Dr. Justin Feinstein details findings from NIH-funded clinical trials regarding the safety and efficacy of floating for patients with severe mental health issues. Results indicate a significant reduction in muscle tension and a 14-point drop on the Spielberger state anxiety inventory after a single session. The Float Research Collective was established to advocate for insurance coverage of this therapy to make it accessible to vulnerable populations.

Dr. Feinstein explains his decision to leave the Laureate Institute for Brain Research to form the Float Research Collective. He felt that the slow, iterative pace of institutional research was insufficient to address the urgent addiction epidemic. By operating independently, he aims to accelerate the process of getting flotation recognized as a subsidized medical treatment by governments and insurance providers.

The 1980 Bayh-Dole Law is identified as a turning point that removed barriers between academia and the pharmaceutical industry, leading to corrupting financial ties. Government agencies like the CDC and NIH now hold joint patents with private companies, creating a financial incentive to increase vaccine schedules. The 1986 National Childhood Vaccine Injury Act is criticized for granting liability protection to manufacturers, which Sharov claims removed the incentive for rigorous safety testing.

The host previews the second hour of the interview available to Plus members, which covers topics such as the Trump administration's vaccine safety commission and state secession trends. The extended discussion also explores whether vaccine-induced aluminum damage can be reversed through detoxification. Carlwood encourages listeners to use the new THC Plus gifting option to share the show with friends and family.

Greg Carlwood discusses Richard M. Krause, the predecessor to Anthony Fauci at the NIAID, who was a Rockefeller-trained physician. Carlwood credits Krause with reintroducing the "return of microbes" narrative, which he argues steered medical science away from terrain theory and back toward a focus on viruses.

Anthony Fauci and the NIH are accused of bypassing safety regulations by funding gain-of-function research at the Wuhan lab in China. Francis Boyle’s perspective is cited, suggesting that international biological weapons codes must be invoked to stop scientists from conducting hazardous research under the guise of civilian medicine.

Del Bigtree details ICAN's legal wins, including a lawsuit forcing the FDA to admit they have no safety trials for administering flu and Tdap vaccines to pregnant women. He highlights the government's failure to conduct mandated safety reporting as required by the 1986 compensation act.

Mark Sloan critiques the current medical research landscape, alleging that organizations like the NIH only fund studies within the genetic or receptor-based paradigms. He argues that this focus allows the pharmaceutical industry to market thousands of different pills for supposedly distinct conditions. In contrast, a metabolic understanding of health suggests that a small number of foods and treatments can address a wide array of diseases, which is less profitable for the medical establishment.

The timeline of Dr. Julie Gerberding’s departure from the CDC to Merck is linked to the discovery of Poul Thorsen’s embezzlement. Grundvig explains how Thorsen managed to continue working at various universities, including Drexel and Johns Hopkins, even after his resignation from Aarhus University. Despite the outstanding warrant for his arrest, Thorsen reportedly continues to receive funding and recognition for scientific studies.